ABBV
$188.85
▼-0.64%
Stock
AbbVie Inc. Common Stock
Official Company Name: AbbVie Inc.
Stock Symbol: ABBV
Stock Market: New York Stock Exchange - NYSE
Currency: United States dollar - USD
ABBV - Stock Indices
ABBV Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▲+17.48%
Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
United States
Company Description
AbbVie Inc. is a pharmaceutical company. It is dedicated to the research and development, manufacturing, and marketing of medicine for a number of chronic diseases including autoimmune diseases, leukemia, lymphoma, hepatitis C, and HIV. It is also engaged in the treatment of pancreatic, thyroidal, and other hormonal insufficiencies.
ABBV Stock Data
| Open | $188.97 |
| High | $189.72 |
| Low | $185.50 |
| Close | $188.85 |
| Volume | 345,364 |
| Previous Close | $190.07 |
| 1-Day Change | -1.22 |
| 1-Year Change | 28.10 |
| Average Daily Volume | 6,132,707 |
| 52-Week High | $216.66 |
| 52-Week Low | $154.79 |
Ratios as of Jan. 25, 2025
| Beta | 0.61 |
| Trailing PE | 59.47 |
| Forward PE | 14.07 |
Unlock Financial AI: get advanced tools and data with a free trial of Disfold AI
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.